Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Rani Therapeutics Holdings Inc (NASDAQ: RANI) closed the day trading at $2.5 up 5.04% from the previous closing price of $2.38. In other words, the price has increased by $5.04 from its previous closing price. On the day, 13.84 million shares were traded. RANI stock price reached its highest trading level at $2.601 during the session, while it also had its lowest trading level at $2.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Oppenheimer on August 02, 2024, initiated with a Outperform rating and assigned the stock a target price of $17.
On June 14, 2024, Maxim Group started tracking the stock assigning a Buy rating and target price of $15.
On June 13, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $10.Rodman & Renshaw initiated its Buy rating on June 13, 2024, with a $10 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 23 ’25 when IMRAN MIR A bought 2,083,334 shares for $0.60 per share. The transaction valued at 1,260,417 led to the insider holds 2,083,334 shares of the business.
South Cone Investments Limited sold 4,000,000 shares of RANI for $11,074,000 on Oct 21 ’25. The 10% Owner now owns 2,379,194 shares after completing the transaction at $2.77 per share. On Oct 20 ’25, another insider, South Cone Investments Limited, who serves as the 10% Owner of the company, sold 1,923,000 shares for $2.41 each. As a result, the insider received 4,637,314 and left with 6,379,194 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RANI now has a Market Capitalization of 306589440 and an Enterprise Value of 127568568. For the stock, the TTM Price-to-Sale (P/S) ratio is 149.73. Its current Enterprise Value per Revenue stands at 106.307 whereas that against EBITDA is -2.864.
Stock Price History:
The Beta on a monthly basis for RANI is 0.39, which has changed by -0.0517928 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, RANI has reached a high of $3.87, while it has fallen to a 52-week low of $0.39. The 50-Day Moving Average of the stock is 166.95%, while the 200-Day Moving Average is calculated to be 161.50%.
Shares Statistics:
Over the past 3-months, RANI traded about 16.41M shares per day on average, while over the past 10 days, RANI traded about 25246470 shares per day. A total of 47.90M shares are outstanding, with a floating share count of 40.07M. Insiders hold about 16.34% of the company’s shares, while institutions hold 32.79% stake in the company. Shares short for RANI as of 1760486400 were 118781 with a Short Ratio of 0.01, compared to 1757894400 on 63982. Therefore, it implies a Short% of Shares Outstanding of 118781 and a Short% of Float of 0.31.
Earnings Estimates
The dynamic stock of Rani Therapeutics Holdings Inc (RANI) is currently being evaluated by a team of 3.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.04 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.39 and -$0.59 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$0.33, with 3.0 analysts recommending between -$0.17 and -$0.45.
Revenue Estimates
A total of 4 analysts have provided revenue estimates for RANI’s current fiscal year. The highest revenue estimate was $10.17M, while the lowest revenue estimate was $172k, resulting in an average revenue estimate of $2.69M. In the same quarter a year ago, actual revenue was $1.03M
